Revolution Medicines, Inc. RVMD Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revolution Medicines, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revolution Medicines, Inc.'s accrued expenses and other liabilities?
- Revolution Medicines, Inc. (RVMD) reported accrued expenses and other liabilities of -$16.74M in Q1 2026.
- How has Revolution Medicines, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Revolution Medicines, Inc.'s accrued expenses and other liabilities decreased by 1180.6% year-over-year, from $1.55M to -$16.74M.
- What is the long-term trend for Revolution Medicines, Inc.'s accrued expenses and other liabilities?
- Over 2 years (2021 to 2025), Revolution Medicines, Inc.'s accrued expenses and other liabilities has grown at a 258.8% compound annual growth rate (CAGR), from $8.72M to $112.27M.